抗白介素抗体在哮喘治疗方面的研究进展

sthma is a chronic inflammatory disease that affects human health worldwide. Although most patients can achieve good control of asthma, 5%-10% patients are suffering from severe asthma, which is uncontrolled by traditional therapy. Interleukin 4,5,9,13, which are mainly secreted by Th2 cell，play the dominant role in the induction and effector phases of airway inammation and hyperreaction. Nowadays many anti-interleukin antibodies, as a promising novel therapy, have entered into the phase of clinical trials. This article reviewed the role of these cytokines played in the pathogenesis of asthma and the new development of anti-interleukin antibodies in the therapies of asthma.